FDA guidance
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment
FDA guidance · Draft · issued Mar 11, 2014
Key facts
| Title | Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment |
|---|---|
| Status | Draft |
| Issue date | Mar 11, 2014 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2014-D-0264 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents